| Title |
100 cc 3% sodium chloride bolus: a novel treatment for hyponatremic encephalopathy
|
|---|---|
| Published in |
Metabolic Brain Disease, March 2010
|
| DOI | 10.1007/s11011-010-9173-2 |
| Pubmed ID | |
| Authors |
Michael L. Moritz, Juan Carlos Ayus |
| Abstract |
Hyponatremic encephalopathy is a potentially lethal condition with numerous reports of death or permanent neurological injury. The optimal treatment for hyponatremic encephalopathy remains controversial. We have introduced a unified approach to the treatment of hyponatremic encephalopathy which uses 3% NaCl (513 mEq/L) bolus therapy. Any patient with suspected hyponatremic encephalopathy should receive a 2 cc/kg bolus of 3% NaCl with a maximum of 100 cc, which could be repeated 1-2 times if symptoms persist. The approach results in a controlled and immediate rise in serum sodium with little risk of inadvertent overcorrection. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 2 | 50% |
| United States | 1 | 25% |
| Argentina | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Scientists | 1 | 25% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Yemen | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 47 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 7 | 14% |
| Student > Doctoral Student | 7 | 14% |
| Other | 5 | 10% |
| Student > Bachelor | 5 | 10% |
| Researcher | 5 | 10% |
| Other | 14 | 29% |
| Unknown | 6 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 73% |
| Business, Management and Accounting | 1 | 2% |
| Nursing and Health Professions | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 5 | 10% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2017.
All research outputs
#3,601,807
of 24,410,879 outputs
Outputs from Metabolic Brain Disease
#157
of 1,147 outputs
Outputs of similar age
#13,778
of 97,077 outputs
Outputs of similar age from Metabolic Brain Disease
#1
of 6 outputs
Altmetric has tracked 24,410,879 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,147 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,077 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them